热门资讯> 正文
周六报道，Vertex宣布对5-11岁儿童进行的CASGEVY研究显示，与12岁及以上儿童相比，具有变革潜力、一致的有效性和安全性
2025-12-08 17:35
- - Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -
- - Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -
- - Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 -
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
